

PATENT APPLICATION

ATTORNEY DOCKET NO. 72535



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Hans KLINGEMANN	) CERTIFICATE OF MAILING
Serial No.:	10/008,955	) I hereby certify that this paper is being deposited with the United States ) Postal Service as first class mail in an
Filed:	December 7, 2001	envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on this date.
Title:	NATURAL KILLER CELL LINES AND METHODS OF USE	) 20231, on this date.
Group Art Unit:		) 2/12/02 ) Date Registration No. 30,562 Attorney for Applicant
Examiner:		)

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §§1.97 and 1.98, Applicant, his undersigned attorney and assignee submit the following information in connection with the above-identified application.

The following United States Patents are listed in chronological order:

## **UNITED STATES PATENT DOCUMENTS**

Patent No.	<u>Inventors</u>	<u>Issue Date</u>
5,272,082 5,772,995 5,981,705	Santoli et al. Fakhrai et al. Kornbluth	December 21, 1993 June 30, 1998 November 9, 1999
•		

274550

#### **FOREIGN PATENT DOCUMENTS**

<u>Document No.</u> <u>Country</u> <u>Effective Date</u>

WO 94/262841 PCT November 24, 1994

### **OTHER REFERENCES**

Gong Jiang-Hong, et al., "Characterization of a Human Cell Line (NK-92) with Phenotypical and Functional Characteristics of Activated Natural Killer Cells", LEUKEMIA, Vol. 8, No. 4 (April), 1994: pp. 652-658.

Klingemann, Hans-Georg, et al., "A cytotoxic ND-cell line (NK-92) for ex vivo purging of leukemia from blood", <u>Biology of Blood and Marrow</u> Transplantation, 2:68-75 (1996).

Wong, E., et al., "Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12, <u>Bone Marrow Transplantation</u>, (1996) 18, pp. 63-71.

Long, G. S., et al., "Lymphokine-Activated Killer Cell Purging of Leukemia Cells from Bone Marrow Prior to Syngeneic Transplantation", <u>Transplantation</u>, Vol. 46, 433-438, No. 3, September 1988.

Gambarcorti-Passerini, C., et al., "Selective purging by human interleukin-2 activated lyumphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells", <u>British Journal of Haematology</u>, 1991, 78, pp. 197-205.

Robertson, M. J., et al., "Biology and Clinical Relevance of Human Natural Killer Cells", Blood, Vol. 76, No. 12, (December 15), 1990: pp. 2421-2438.

Ellis, T. M., et al., "Functional Heterogeneity of Leu 19"bright" + and Leu 19"dim" + Lymphokine-Activated Killer Cells", <u>The Journal of Immunology</u>, Vol. 142, April 15, 1989, No. 8, pp. 2949-2954.

Ades, E. W., "Lymphokine-Activated Killer Cell Lysis of Human Neuroblatoma Cells: A Model for Purging Tumor Cells from Bone Marrow", Clinical Immunology and Immunopathology, 46, pp. 150-156 (1988).

Tsuchiyama, J. et al., "Characterization of a Novel Human Natural Killer-Cell Line (ND-YS) Established from Natural Killer Cell Lymphoma/Leukemia Associated with Epstein-Barr Virus Infection", <u>Blood</u>, Vol. 92, No. 4, (August 15), 1988: pp. 1374-1383.

Ingo, G. H., et al., "Use of a SCID Mouse/Human Lymphoma Model to Evaluate Cytokine-induced Killer Cells with Potent Antitumor Cell Activity", <u>J. Exp. Med.</u>, Vol. 174, July 1991, pp. 139-149.

Hercend, T., et al., "Phenotypic and functional heterogeity of human cloned natural killer cell lines", Nature, Vol. 301, January 13, 1983, pp. 158-160.

Alderson, M. R., "Interleukin 7 Enhances Cytolytic T Lymphocyte Generation and Induces Lymphokine-activated Killer Cells from Human Peripheral Blood", <u>J. Exp. Med</u>, Vol. 172, August 1990, pp. 577-787.

Robertson, M. J., et al., "Response of Human Natural Killer (NK) Cells to NK Cell Stimulatory Factor (NKSF): Cytolytic Activity and Proliferation of NK Cells are Differentially Regulated by NKSF", <u>J. Exp. Med.</u>, March 1992, pp. 779-788.

Phillips, J. H., et al., "Dissection of the Lymphokine-Activated Killer Phenomenon", J. Exp. Med., Vol. 164, September 1986, pp. 814-825.

Rosenberg, S. A., et al., "Special Report - Observation on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastic Cancer", <u>The New England Journal of Medicine</u>, Vol. 313, No. 23, Dec. 5, 1985, pp. 1485-1492.

Yodoi, J., et al., "TCGF (IL 2)-Receptor Inducing Factor(s)", <u>Journal of Immunology</u>, Vol. 134, No. 3, March 1985, pp. 1623-1630.

Mule, J. J., et al., "Adoptive Immunotherapy of Established Pulmonary Metastes with LAK Cells and Recombinant Interleukin-2", <u>Science</u>, Vol. 225, pp. 1487-1489.

Komiyama, A., et al., "Childhood Lymphoblastic Leukemia with Natural Killer Activity: Establishment of the Leukemia Cell Lines Retaining the Activity", Blood, Vol. 60, No. 6 (December), 1992, pp. 1429-1436.

Fernandez, L. A, et al., "Aggressive Natural Killer Cell Leukemia in an Adult With Establishment of an NK Cell Line", <u>Blood</u>, Vol. 67, No. 4 (April), 1986: pp. 925-930.

Suzuki, N., et al., "Natural Killer Lines and Clones with Apparent Antigen Specificity", J. Exp. Med., Vol. 172, August 1990, pp. 457-462.

Chin, Keh-Chuang, et al., "Activation and Transdominant Suppression of MHC Class II and HLA-DMB Promoters by a Series of C-Terminal Class II Transactivator Deletion Mutants", <u>The Journal of Immunology</u>, 0022-1767, 1997, pp. 2790-2794.

Schouten, Govert J., et al., "Downregulation of MHC Class I expression due to interference with p105-NFKB1 processing by Ad12E1A", The EMBO Journal, Vol. 14, No. 7, pp. 1498-1507, 1995.

Submitted herewith is Form PTO-1449 listing the above-identified references. Copies of the listed patents and publications are not provided herewith pursuant to 37 C.F.R. §1.98(d) since they were previously cited by or submitted to the Patent and Trademark Office during the prosecution of the above-identified co-pending applications.

PATENT APPLICATION

Appln No. 10/008,955 Filed December 7, 2001

Pursuant to 37 CFR §1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b).

Respectfully submitted,


FITCH, EXEN, TABIN & FLANNERY

Dated: February 12, 2002

y <u>r</u> Biobard A

Reg. No. 30,562

120 South LaSalle Street Suite 1600 Chicago, Illinois 60603-3406 (312) 577-7000





Sheet 1 of

**Application Number Docket Number** Form PTO-1449 10/008,955 72535 INFORMATION DISCLOSURE CITATION Applicant IN AN APPLICATION Hans KLINGEMANN **Group Art Unit** (Use several sheets if necessary) Filing Date December 7, 2001 **U. S. PATENT DOCUMENTS FILING EXAMINER** SUB DATE IF CLASS DOCUMENT NUMBER DATE NAME INITIAL CLASS APPROP. 2 12/21/93 Santoli et al. 5 2 0 Fakhrai et al. 2 5 5 9 9 6/30/98 9 7 0 5 11/9/99 Kornbluth 5 8 1 TECH CENTER 1600/2900 FOREIGN PATENT DOCUMENTS Translation **SUB** COUNTRY CLASS **DOCUMENT NUMBER** DATE **CLASS** Yes No 11/24/94 **PCT** WO 94/262841 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Gong Jiang-Hong, et al., "Characterization of a Human Cell Line (NK-92) with Phenotypical and Functional Characteristics of Activated Natural Killer Cells", LEUKEMIA, Vol. 8, No. 4 (April), 1994: pp. 652-658 Klingemann, Hans-Georg, et al., "A cytotoxic ND-cell line (NK-92) for ex vivo purging of leukemia from blood", Biology of Blood and Marrow Transplantation, 2:68-75 (1996) Wong, E., et al., "Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12, Bone Marrow Transplantation, (1996) 18, pp. 63-71 Long, G. S., et al., "Lymphokine-Activated Killer Cell Purging of Leukemia Cells from Bone Marrow Prior to Syngeneic Transplantation", Transplantation, Vol. 46, 433-438, No. 3, September 1988 Gambarcorti-Passerini, C., et al., "Selective purging by human interleukin-2 activated lyumphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells", British Journal of Haematology, 1991, 78, pp. 197-205. DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant

**EXAMINER** 



				FFR	27	2002	83		SHIGINALLY FILED	SI	neet <u>2</u>	of	5		
Form PTO-	144	9	P. F.		ABEV		<b>E</b>		Docket Number 72535		Application 10/008		ber		
INFO	RM	OITA IN A		ISCL	.osu	JRE (		TION	Applicant Hans KLINGEMANN						
	(U	se sev	eral	sheet	s if ne	ecess	ary)		Filing Date December 7, 2001	_	Group Art Unit				
								U. S. PATI	ENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER DATE								NAME	CLASS	SUB CLASS	DA	ING TE IF PROP.		
· <del></del>				-						REC	EIV	ED			
										MAH					
								ļ		ECH CE	NTER 16	)0/29(	<u> </u>		
	_			_		-				· .					
		$\vdash$								-					
				-		┢									
	<u> </u>	11		<u> </u>		<b></b>	1	FOREIGN PA	ATENT DOCUMENTS	<u> </u>	-				
										01.400	SUB	Tran	slation		
		DO	CUM	ENT	NUME	BER		DATE	COUNTRY	CLASS	CLASS	Yes	No		
				-											
	<u> </u>		-					OTHER	DOCUMENTS (Including Author	, Title, Date	, Pertinent	Pages,	Etc.)		
		ertsor				"Biolo	gy ar	nd Clinical Relev	ance of Human Natural Killer Cells*, <u>B</u>	l <u>ood</u> , Vol. 7	6, No. 12,	(Decem	ber 15),		
,	Ellis	, T. M	l., et	al., "l	Funct	ional	Heter	ogeneity of Leu 189, No. 8, pp. 3	19 <sup>'bright'</sup> and Leu 19 <sup>'dim'</sup> Lymphokine	-Activated	Killer Cells"	, The Jo	ournal of		
-	Ade	es, E. \	w., *	Lymp	hokin	e-Act	ivate	d Killer Cell Lysi	s of Human Neuroblatoma Cells: A Mo	del for Purg	ing Tumor	Cells fro	om Bone		
<u> </u>	Mai	row",	Clini	ical In	nmun	ology	and	Immunopatholog	y, 46, pp. 150-156 (1988) Human Natural Killer-Cell Line (ND-Y			-			
	Lyn	phom	a/Le	ukemi	ia Ass	ociat	ed w	ith Epstein-Barr	Virus Infection", Blood, Vol. 92, No. 4	, (August 1	5), 1988։ բ	p. 137	4-1383		
	Inge	o, G. H	l., et	al., "l	Jse of	a SC	ID Mo	ouse/Human Lym	phoma Model to Evaluate Cytokine-ind	luced Killer (	Cells with P	otent A	ntitumor		

**EXAMINER** 

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant

DATE CONSIDERED






Sheet \_ of .

	Application Number
535	10/008,955

Form PTO-	1449	THE P	TRAC	URE CI		Docket Number 72535		Application Number 10/008,955					
INFO		ON DIS AN AP			TATION	Applicant Hans KLINGEMANN							
	(Use s	everal sh	eets if	necessary	v) 	Filing Date Group Art Unit December 7, 2001							
		-			U. S. PAT	ENT DOCUMENTS							
EXAMINER INITIAL	D	OCUMEN	NT NUM	MBER	DATE	NAME	CLASS	SUB CLASS	DA	FILING DATE IF APPROP.			
		1-1-											
							RE	CEIN	/EE	<del></del>			
								R → 4 2	ļ				
		$oxed{+}$					ECH CE	NTER 10	00/29	)00			
					FOREIGN P	ATENT DOCUMENTS			1				
	DOCUMENT NUMBER DATE					COUNTRY	CLASS	SUB CLASS	Tran Yes	nslation No			
	-												
				-						<b>-</b>			
	Hercenc	, T., et al	I., "Phe	notypic a		R DOCUMENTS (Including Aut							
	1983, p	p. 158-1	60		nd functional heter	rogeity of human cloned natural kille	r cell lines", <u>Na</u>	ture, Vol. 3	01, Jan	uary 13,			
	1983, p Alderson Human	p. 158-1 n, M. R., Periphera	"Interle	eukin 7 Eı ", J. Exp	nd functional heter nhances Cytolytic Med, Vol. 172, A	rogeity of human cloned natural killer T Lymphocyte Generation and Induc lugust 1990, pp. 577-787	r cell lines", <u>Na</u> es Lymphokine	ture, Vol. 3 e-activated	Killer C	ells from			
	Alderson Human Roberts Prolifera	n, M. R., Periphera on, M. J., ation of N	"Interle al Blood , et al., IK Cells	eukin 7 Er ", J. Exp "Respons are Diffe	nd functional heter nhances Cytolytic Med, Vol. 172, A se of Human Natur rentially Regulated	T Lymphocyte Generation and Induction  T Lymphocyte Generation and Induction  August 1990, pp. 577-787  al Killer (NK) Cells to NK Cell Stimula  by NKSF", J. Exp. Med., March 1	r cell lines", <u>Na</u> es Lymphokino atory Factor (NI 992, pp. 779-7	ture, Vol. 3 e-activated KSF): Cytol 788	Killer C	ells from			
	Alderson Human Roberts Prolifera	n, M. R., Periphera on, M. J., ation of N	"Interle al Blood , et al., IK Cells	eukin 7 Er ", J. Exp "Respons are Diffe	nd functional heter nhances Cytolytic Med, Vol. 172, A se of Human Natur rentially Regulated	T Lymphocyte Generation and Inducting 1990, pp. 577-787	r cell lines", <u>Na</u> es Lymphokino atory Factor (NI 992, pp. 779-7	ture, Vol. 3 e-activated KSF): Cytol 788	Killer C	ells from			
	Alderson Human Roberts Prolifera Phillips, 814-82 Rosenbe Cells an	n, M. R., Periphera on, M. J., ation of N J. H., et 5	"Interlead Blood , et al., K Cells al., "Di ., et al., binant I	"Respons are Diffe ssection "Special nterleuki	nhances Cytolytic Med, Vol. 172, A se of Human Natur rentially Regulated of the Lymphokine Report - Observati	T Lymphocyte Generation and Induction  T Lymphocyte Generation and Induction  August 1990, pp. 577-787  al Killer (NK) Cells to NK Cell Stimula  by NKSF", J. Exp. Med., March 1	ees Lymphoking story Factor (NI 992, pp. 779-7 xp. Med., Vol.	ture, Vol. 3 e-activated KSF): Cytol 788 164, Septe	Killer C ytic Act ember 1	ells from ivity and 986, pp.			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant





Sheet \_ **Application Number** 10/008,955 Group Art Unit **FILING SUB** DATE IF **CLASS CLASS** APPROP.

Form PTO-1449

**EXAMINER** 

INITIAL

#### INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

**DOCUMENT NUMBER** 

Science, Vol. 225, pp. 1487-1489

67, No. 4 (April), 1986: pp. 925-930

72535 **Applicant** 

DATE

Hans KLINGEMANN

Filing Date

**Docket Number** 

December 7, 2001

NAME

**U. S. PATENT DOCUMENTS** 

										MAK -	₽ ZUU	2	
									TECH	CENTER	1600	<del>)/2900</del>	
						-							
							FOREIGN PA	TENT DOCUMENTS					
										SUB	Translation		
	DO	СПМ	ENT I	NUME	BER		DATE	COUNTRY	CLASS	CLASS	Yęs	No	
										•			
/							OTHER	DOCUMENTS (Including Author,	Title, Date	, Pertinent	Pages,	Etc.)	

**EXAMINER** 

457-462

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant

Retaining the Activity", Blood, Vol. 60, No. 6 (December), 1992, pp. 1429-1436

Yodoi, J., et al., "TCGF (IL 2)-Receptor Inducing Factor(s)", <u>Journal of Immunology,</u> Vol. 134, No. 3, March 1985, pp. 1623-1630 Mule, J. J., et al., "Adoptive Immunotherapy of Established Pulmonary Metastes with LAK Cells and Recombinant Interleukin-2",

Komiyama, A., et al., "Childhood Lymphoblastic Leukemia with Natural Killer Activity: Establishment of the Leukemia Cell Lines

Fernandez, L. A, et al., "Aggressive Natural Killer Cell Leukemia in an Adult With Establishment of an NK Cell Line", <u>Blood</u>, Vol.

Suzuki, N., et al., "Natural Killer Lines and Clones with Apparent Antigen Specificity", J. Exp. Med., Vol. 172, August 1990, pp.



				1=	, rec	, ,	ZUUZ	<u>س</u>		S	heet 5	of	5	
Form PTO-	144	9		7	Ay.	PARI	NA DY	<u></u>	Docket Number Application Number 72535 10/008,955					
INFO	ORM			ISCL	OSU ICA	JRE (	CITA	TION	Applicant Hans KLINGEMANN					
	(U	lse se	veral	sheet	s if n	ecess	ary)		Filing Date Group Art Unit December 7, 2001					
								U. S. PATI	ENT DOCUMENTS					
EXAMINER INITIAL	DOCUMENT NUMBER					BER		DATE	NAME	CLASS	SUB CLASS	D/	LING ATE IF PROP.	
			_		ļ									
	_	ļ			ļ						\ <u>\</u>			
					<u> </u>					HEC	CEIV	EL	)	
					<u> </u>					MAF	<u>- 4 20</u>	02		
,	ļ	ļ	ļ	<u> </u>						TECH CE	UTER 16	זסכיותו	YI .	
	_	<u> </u>								TEOTIOLI	11211 100	10/23(	<u> </u>	
					ļ		_							
	<u> </u>	<b> </b>		_			_			· ·				
		L.,	<u> </u>	<u> </u>		<u> </u>	<u> </u>				<u> </u>			
		-		· ·				FOREIGN PA	ATENT DOCUMENTS	7	Ι			
		DC	CUM	ENT	NUME	BER		DATE	COUNTRY	CLASS	SUB CLASS	Translation		
	┝									Ì		Yes	No	
	-						•							
	-										-			
		<del></del>								_				
										1				
	-									_				
								OTUE	DOCUMENTS (Including Author	r Title Date	Portinont	Pages	Eta l	
	Chi	n, Kel	n-Chu	ang, e	et al.,	"Acti	ivation	n and Transdom	inant Suppression of MHC Class II ar The Journal of Immunology, 0022-1	d HLA-DMB	Promoters I	oy a Se		
	Sch	nouter	ı, Gov	vert J	., et	al., "l	Down	regulation of M	HC Class I expression due to interfet 1498-1507, 1995				ssing by	
	70	1,2,1,1,5	<u>, 11</u>	- E141	20 00	, u. 11d	., + 01.	. +, 110. /, pp.			- "			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant

**EXAMINER** 

DATE CONSIDERED